ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Neuromyelitis Optica Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-17Z8202
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global and United States Drugs for Neuromyelitis Optica Market Insights Forecast to 2027
BUY CHAPTERS

Global Drugs for Neuromyelitis Optica Market Research Report 2025

Code: QYRE-Auto-17Z8202
Report
July 2025
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Fresenius
TEVA
Sandoz Inc
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL Limited
Grifols S A
Octapharma AG
CBOP

Drugs for Neuromyelitis Optica Market Size

The global market for Drugs for Neuromyelitis Optica was valued at US$ 50.3 million in the year 2024 and is projected to reach a revised size of US$ 63.3 million by 2031, growing at a CAGR of 3.4% during the forecast period.

Drugs for Neuromyelitis Optica Market

Drugs for Neuromyelitis Optica Market

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren"t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Neuromyelitis Optica, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Neuromyelitis Optica.
The Drugs for Neuromyelitis Optica market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Neuromyelitis Optica market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Neuromyelitis Optica manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Drugs for Neuromyelitis Optica Market Report

Report Metric Details
Report Name Drugs for Neuromyelitis Optica Market
Accounted market size in year US$ 50.3 million
Forecasted market size in 2031 US$ 63.3 million
CAGR 3.4%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Acute Attack
  • Remission Prophylactic Treatment
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Drugs for Neuromyelitis Optica manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Drugs for Neuromyelitis Optica in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Drugs for Neuromyelitis Optica Market growing?

Ans: The Drugs for Neuromyelitis Optica Market witnessing a CAGR of 3.4% during the forecast period 2025-2031.

What is the Drugs for Neuromyelitis Optica Market size in 2031?

Ans: The Drugs for Neuromyelitis Optica Market size in 2031 will be US$ 63.3 million.

Who are the main players in the Drugs for Neuromyelitis Optica Market report?

Ans: The main players in the Drugs for Neuromyelitis Optica Market are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP

What are the Application segmentation covered in the Drugs for Neuromyelitis Optica Market report?

Ans: The Applications covered in the Drugs for Neuromyelitis Optica Market report are Acute Attack, Remission Prophylactic Treatment

What are the Type segmentation covered in the Drugs for Neuromyelitis Optica Market report?

Ans: The Types covered in the Drugs for Neuromyelitis Optica Market report are Glucocorticoids, Immunotherapies, Other

Recommended Reports

Neurodegenerative Treatments

Ophthalmic Disorders

CNS and Paralysis

1 Drugs for Neuromyelitis Optica Market Overview
1.1 Product Definition
1.2 Drugs for Neuromyelitis Optica by Type
1.2.1 Global Drugs for Neuromyelitis Optica Market Value Comparison by Type (2024 VS 2031)
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Other
1.3 Drugs for Neuromyelitis Optica by Application
1.3.1 Global Drugs for Neuromyelitis Optica Market Value by Application (2024 VS 2031)
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Global Drugs for Neuromyelitis Optica Market Size Estimates and Forecasts
1.4.1 Global Drugs for Neuromyelitis Optica Revenue 2020-2031
1.4.2 Global Drugs for Neuromyelitis Optica Sales 2020-2031
1.4.3 Global Drugs for Neuromyelitis Optica Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Drugs for Neuromyelitis Optica Market Competition by Manufacturers
2.1 Global Drugs for Neuromyelitis Optica Sales Market Share by Manufacturers (2020-2025)
2.2 Global Drugs for Neuromyelitis Optica Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Drugs for Neuromyelitis Optica Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Drugs for Neuromyelitis Optica, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs for Neuromyelitis Optica, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Neuromyelitis Optica, Product Type & Application
2.7 Global Key Manufacturers of Drugs for Neuromyelitis Optica, Date of Enter into This Industry
2.8 Global Drugs for Neuromyelitis Optica Market Competitive Situation and Trends
2.8.1 Global Drugs for Neuromyelitis Optica Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Drugs for Neuromyelitis Optica Players Market Share by Revenue
2.8.3 Global Drugs for Neuromyelitis Optica Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for Neuromyelitis Optica Market Scenario by Region
3.1 Global Drugs for Neuromyelitis Optica Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Drugs for Neuromyelitis Optica Sales by Region: 2020-2031
3.2.1 Global Drugs for Neuromyelitis Optica Sales by Region: 2020-2025
3.2.2 Global Drugs for Neuromyelitis Optica Sales by Region: 2026-2031
3.3 Global Drugs for Neuromyelitis Optica Revenue by Region: 2020-2031
3.3.1 Global Drugs for Neuromyelitis Optica Revenue by Region: 2020-2025
3.3.2 Global Drugs for Neuromyelitis Optica Revenue by Region: 2026-2031
3.4 North America Drugs for Neuromyelitis Optica Market Facts & Figures by Country
3.4.1 North America Drugs for Neuromyelitis Optica Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Drugs for Neuromyelitis Optica Sales by Country (2020-2031)
3.4.3 North America Drugs for Neuromyelitis Optica Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for Neuromyelitis Optica Market Facts & Figures by Country
3.5.1 Europe Drugs for Neuromyelitis Optica Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Drugs for Neuromyelitis Optica Sales by Country (2020-2031)
3.5.3 Europe Drugs for Neuromyelitis Optica Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Neuromyelitis Optica Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for Neuromyelitis Optica Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Drugs for Neuromyelitis Optica Sales by Region (2020-2031)
3.6.3 Asia Pacific Drugs for Neuromyelitis Optica Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Drugs for Neuromyelitis Optica Market Facts & Figures by Country
3.7.1 Latin America Drugs for Neuromyelitis Optica Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Drugs for Neuromyelitis Optica Sales by Country (2020-2031)
3.7.3 Latin America Drugs for Neuromyelitis Optica Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drugs for Neuromyelitis Optica Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Neuromyelitis Optica Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Drugs for Neuromyelitis Optica Sales by Country (2020-2031)
3.8.3 Middle East and Africa Drugs for Neuromyelitis Optica Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Neuromyelitis Optica Sales by Type (2020-2031)
4.1.1 Global Drugs for Neuromyelitis Optica Sales by Type (2020-2025)
4.1.2 Global Drugs for Neuromyelitis Optica Sales by Type (2026-2031)
4.1.3 Global Drugs for Neuromyelitis Optica Sales Market Share by Type (2020-2031)
4.2 Global Drugs for Neuromyelitis Optica Revenue by Type (2020-2031)
4.2.1 Global Drugs for Neuromyelitis Optica Revenue by Type (2020-2025)
4.2.2 Global Drugs for Neuromyelitis Optica Revenue by Type (2026-2031)
4.2.3 Global Drugs for Neuromyelitis Optica Revenue Market Share by Type (2020-2031)
4.3 Global Drugs for Neuromyelitis Optica Price by Type (2020-2031)
5 Segment by Application
5.1 Global Drugs for Neuromyelitis Optica Sales by Application (2020-2031)
5.1.1 Global Drugs for Neuromyelitis Optica Sales by Application (2020-2025)
5.1.2 Global Drugs for Neuromyelitis Optica Sales by Application (2026-2031)
5.1.3 Global Drugs for Neuromyelitis Optica Sales Market Share by Application (2020-2031)
5.2 Global Drugs for Neuromyelitis Optica Revenue by Application (2020-2031)
5.2.1 Global Drugs for Neuromyelitis Optica Revenue by Application (2020-2025)
5.2.2 Global Drugs for Neuromyelitis Optica Revenue by Application (2026-2031)
5.2.3 Global Drugs for Neuromyelitis Optica Revenue Market Share by Application (2020-2031)
5.3 Global Drugs for Neuromyelitis Optica Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Drugs for Neuromyelitis Optica Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Fresenius
6.2.1 Fresenius Company Information
6.2.2 Fresenius Description and Business Overview
6.2.3 Fresenius Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Fresenius Drugs for Neuromyelitis Optica Product Portfolio
6.2.5 Fresenius Recent Developments/Updates
6.3 Teva
6.3.1 Teva Company Information
6.3.2 Teva Description and Business Overview
6.3.3 Teva Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Teva Drugs for Neuromyelitis Optica Product Portfolio
6.3.5 Teva Recent Developments/Updates
6.4 Sandoz
6.4.1 Sandoz Company Information
6.4.2 Sandoz Description and Business Overview
6.4.3 Sandoz Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sandoz Drugs for Neuromyelitis Optica Product Portfolio
6.4.5 Sandoz Recent Developments/Updates
6.5 Intas
6.5.1 Intas Company Information
6.5.2 Intas Description and Business Overview
6.5.3 Intas Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Intas Drugs for Neuromyelitis Optica Product Portfolio
6.5.5 Intas Recent Developments/Updates
6.6 Gyjtrs
6.6.1 Gyjtrs Company Information
6.6.2 Gyjtrs Description and Business Overview
6.6.3 Gyjtrs Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Gyjtrs Drugs for Neuromyelitis Optica Product Portfolio
6.6.5 Gyjtrs Recent Developments/Updates
6.7 NANG KUANG
6.7.1 NANG KUANG Company Information
6.7.2 NANG KUANG Description and Business Overview
6.7.3 NANG KUANG Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.7.4 NANG KUANG Drugs for Neuromyelitis Optica Product Portfolio
6.7.5 NANG KUANG Recent Developments/Updates
6.8 Tianjin Kingyork
6.8.1 Tianjin Kingyork Company Information
6.8.2 Tianjin Kingyork Description and Business Overview
6.8.3 Tianjin Kingyork Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Tianjin Kingyork Drugs for Neuromyelitis Optica Product Portfolio
6.8.5 Tianjin Kingyork Recent Developments/Updates
6.9 Baxter
6.9.1 Baxter Company Information
6.9.2 Baxter Description and Business Overview
6.9.3 Baxter Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Baxter Drugs for Neuromyelitis Optica Product Portfolio
6.9.5 Baxter Recent Developments/Updates
6.10 CSL
6.10.1 CSL Company Information
6.10.2 CSL Description and Business Overview
6.10.3 CSL Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.10.4 CSL Drugs for Neuromyelitis Optica Product Portfolio
6.10.5 CSL Recent Developments/Updates
6.11 Grifols
6.11.1 Grifols Company Information
6.11.2 Grifols Description and Business Overview
6.11.3 Grifols Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Grifols Drugs for Neuromyelitis Optica Product Portfolio
6.11.5 Grifols Recent Developments/Updates
6.12 Octapharma
6.12.1 Octapharma Company Information
6.12.2 Octapharma Description and Business Overview
6.12.3 Octapharma Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Octapharma Drugs for Neuromyelitis Optica Product Portfolio
6.12.5 Octapharma Recent Developments/Updates
6.13 CBOP
6.13.1 CBOP Company Information
6.13.2 CBOP Description and Business Overview
6.13.3 CBOP Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2020-2025)
6.13.4 CBOP Drugs for Neuromyelitis Optica Product Portfolio
6.13.5 CBOP Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Neuromyelitis Optica Industry Chain Analysis
7.2 Drugs for Neuromyelitis Optica Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Neuromyelitis Optica Production Mode & Process Analysis
7.4 Drugs for Neuromyelitis Optica Sales and Marketing
7.4.1 Drugs for Neuromyelitis Optica Sales Channels
7.4.2 Drugs for Neuromyelitis Optica Distributors
7.5 Drugs for Neuromyelitis Optica Customer Analysis
8 Drugs for Neuromyelitis Optica Market Dynamics
8.1 Drugs for Neuromyelitis Optica Industry Trends
8.2 Drugs for Neuromyelitis Optica Market Drivers
8.3 Drugs for Neuromyelitis Optica Market Challenges
8.4 Drugs for Neuromyelitis Optica Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Fresenius
TEVA
Sandoz Inc
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL Limited
Grifols S A
Octapharma AG
CBOP
List of Tables
 Table 1. Global Drugs for Neuromyelitis Optica Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Drugs for Neuromyelitis Optica Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Drugs for Neuromyelitis Optica Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Drugs for Neuromyelitis Optica Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Drugs for Neuromyelitis Optica Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Drugs for Neuromyelitis Optica Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Drugs for Neuromyelitis Optica Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Drugs for Neuromyelitis Optica Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Drugs for Neuromyelitis Optica, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Drugs for Neuromyelitis Optica, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Drugs for Neuromyelitis Optica, Product Type & Application
 Table 12. Global Key Manufacturers of Drugs for Neuromyelitis Optica, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Drugs for Neuromyelitis Optica by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Neuromyelitis Optica as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Drugs for Neuromyelitis Optica Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Drugs for Neuromyelitis Optica Sales by Region (2020-2025) & (K Units)
 Table 18. Global Drugs for Neuromyelitis Optica Sales Market Share by Region (2020-2025)
 Table 19. Global Drugs for Neuromyelitis Optica Sales by Region (2026-2031) & (K Units)
 Table 20. Global Drugs for Neuromyelitis Optica Sales Market Share by Region (2026-2031)
 Table 21. Global Drugs for Neuromyelitis Optica Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Drugs for Neuromyelitis Optica Revenue Market Share by Region (2020-2025)
 Table 23. Global Drugs for Neuromyelitis Optica Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Drugs for Neuromyelitis Optica Revenue Market Share by Region (2026-2031)
 Table 25. North America Drugs for Neuromyelitis Optica Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Drugs for Neuromyelitis Optica Sales by Country (2020-2025) & (K Units)
 Table 27. North America Drugs for Neuromyelitis Optica Sales by Country (2026-2031) & (K Units)
 Table 28. North America Drugs for Neuromyelitis Optica Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Drugs for Neuromyelitis Optica Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Drugs for Neuromyelitis Optica Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Drugs for Neuromyelitis Optica Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Drugs for Neuromyelitis Optica Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Drugs for Neuromyelitis Optica Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Drugs for Neuromyelitis Optica Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Drugs for Neuromyelitis Optica Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Drugs for Neuromyelitis Optica Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Drugs for Neuromyelitis Optica Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Drugs for Neuromyelitis Optica Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Drugs for Neuromyelitis Optica Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Drugs for Neuromyelitis Optica Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Drugs for Neuromyelitis Optica Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Drugs for Neuromyelitis Optica Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Drugs for Neuromyelitis Optica Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Drugs for Neuromyelitis Optica Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Drugs for Neuromyelitis Optica Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Drugs for Neuromyelitis Optica Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Drugs for Neuromyelitis Optica Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Drugs for Neuromyelitis Optica Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Drugs for Neuromyelitis Optica Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Drugs for Neuromyelitis Optica Sales (K Units) by Type (2020-2025)
 Table 51. Global Drugs for Neuromyelitis Optica Sales (K Units) by Type (2026-2031)
 Table 52. Global Drugs for Neuromyelitis Optica Sales Market Share by Type (2020-2025)
 Table 53. Global Drugs for Neuromyelitis Optica Sales Market Share by Type (2026-2031)
 Table 54. Global Drugs for Neuromyelitis Optica Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Drugs for Neuromyelitis Optica Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Drugs for Neuromyelitis Optica Revenue Market Share by Type (2020-2025)
 Table 57. Global Drugs for Neuromyelitis Optica Revenue Market Share by Type (2026-2031)
 Table 58. Global Drugs for Neuromyelitis Optica Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Drugs for Neuromyelitis Optica Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Drugs for Neuromyelitis Optica Sales (K Units) by Application (2020-2025)
 Table 61. Global Drugs for Neuromyelitis Optica Sales (K Units) by Application (2026-2031)
 Table 62. Global Drugs for Neuromyelitis Optica Sales Market Share by Application (2020-2025)
 Table 63. Global Drugs for Neuromyelitis Optica Sales Market Share by Application (2026-2031)
 Table 64. Global Drugs for Neuromyelitis Optica Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Drugs for Neuromyelitis Optica Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Drugs for Neuromyelitis Optica Revenue Market Share by Application (2020-2025)
 Table 67. Global Drugs for Neuromyelitis Optica Revenue Market Share by Application (2026-2031)
 Table 68. Global Drugs for Neuromyelitis Optica Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Drugs for Neuromyelitis Optica Price (US$/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer Drugs for Neuromyelitis Optica Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Fresenius Company Information
 Table 76. Fresenius Description and Business Overview
 Table 77. Fresenius Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Fresenius Drugs for Neuromyelitis Optica Product
 Table 79. Fresenius Recent Developments/Updates
 Table 80. Teva Company Information
 Table 81. Teva Description and Business Overview
 Table 82. Teva Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Teva Drugs for Neuromyelitis Optica Product
 Table 84. Teva Recent Developments/Updates
 Table 85. Sandoz Company Information
 Table 86. Sandoz Description and Business Overview
 Table 87. Sandoz Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Sandoz Drugs for Neuromyelitis Optica Product
 Table 89. Sandoz Recent Developments/Updates
 Table 90. Intas Company Information
 Table 91. Intas Description and Business Overview
 Table 92. Intas Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Intas Drugs for Neuromyelitis Optica Product
 Table 94. Intas Recent Developments/Updates
 Table 95. Gyjtrs Company Information
 Table 96. Gyjtrs Description and Business Overview
 Table 97. Gyjtrs Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Gyjtrs Drugs for Neuromyelitis Optica Product
 Table 99. Gyjtrs Recent Developments/Updates
 Table 100. NANG KUANG Company Information
 Table 101. NANG KUANG Description and Business Overview
 Table 102. NANG KUANG Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. NANG KUANG Drugs for Neuromyelitis Optica Product
 Table 104. NANG KUANG Recent Developments/Updates
 Table 105. Tianjin Kingyork Company Information
 Table 106. Tianjin Kingyork Description and Business Overview
 Table 107. Tianjin Kingyork Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Tianjin Kingyork Drugs for Neuromyelitis Optica Product
 Table 109. Tianjin Kingyork Recent Developments/Updates
 Table 110. Baxter Company Information
 Table 111. Baxter Description and Business Overview
 Table 112. Baxter Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Baxter Drugs for Neuromyelitis Optica Product
 Table 114. Baxter Recent Developments/Updates
 Table 115. CSL Company Information
 Table 116. CSL Description and Business Overview
 Table 117. CSL Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. CSL Drugs for Neuromyelitis Optica Product
 Table 119. CSL Recent Developments/Updates
 Table 120. Grifols Company Information
 Table 121. Grifols Description and Business Overview
 Table 122. Grifols Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Grifols Drugs for Neuromyelitis Optica Product
 Table 124. Grifols Recent Developments/Updates
 Table 125. Octapharma Company Information
 Table 126. Octapharma Description and Business Overview
 Table 127. Octapharma Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Octapharma Drugs for Neuromyelitis Optica Product
 Table 129. Octapharma Recent Developments/Updates
 Table 130. CBOP Company Information
 Table 131. CBOP Description and Business Overview
 Table 132. CBOP Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. CBOP Drugs for Neuromyelitis Optica Product
 Table 134. CBOP Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Drugs for Neuromyelitis Optica Distributors List
 Table 138. Drugs for Neuromyelitis Optica Customers List
 Table 139. Drugs for Neuromyelitis Optica Market Trends
 Table 140. Drugs for Neuromyelitis Optica Market Drivers
 Table 141. Drugs for Neuromyelitis Optica Market Challenges
 Table 142. Drugs for Neuromyelitis Optica Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Drugs for Neuromyelitis Optica
 Figure 2. Global Drugs for Neuromyelitis Optica Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Drugs for Neuromyelitis Optica Market Share by Type: 2024 & 2031
 Figure 4. Glucocorticoids Product Picture
 Figure 5. Immunotherapies Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Drugs for Neuromyelitis Optica Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Drugs for Neuromyelitis Optica Market Share by Application: 2024 & 2031
 Figure 9. Acute Attack
 Figure 10. Remission Prophylactic Treatment
 Figure 11. Global Drugs for Neuromyelitis Optica Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Drugs for Neuromyelitis Optica Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Drugs for Neuromyelitis Optica Sales (2020-2031) & (K Units)
 Figure 14. Global Drugs for Neuromyelitis Optica Average Price (US$/Unit) & (2020-2031)
 Figure 15. Drugs for Neuromyelitis Optica Report Years Considered
 Figure 16. Drugs for Neuromyelitis Optica Sales Share by Manufacturers in 2024
 Figure 17. Global Drugs for Neuromyelitis Optica Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Drugs for Neuromyelitis Optica Players: Market Share by Revenue in Drugs for Neuromyelitis Optica in 2024
 Figure 19. Drugs for Neuromyelitis Optica Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Drugs for Neuromyelitis Optica Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Drugs for Neuromyelitis Optica Sales Market Share by Country (2020-2031)
 Figure 22. North America Drugs for Neuromyelitis Optica Revenue Market Share by Country (2020-2031)
 Figure 23. United States Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Drugs for Neuromyelitis Optica Sales Market Share by Country (2020-2031)
 Figure 26. Europe Drugs for Neuromyelitis Optica Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Drugs for Neuromyelitis Optica Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Drugs for Neuromyelitis Optica Revenue Market Share by Region (2020-2031)
 Figure 34. China Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Drugs for Neuromyelitis Optica Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Drugs for Neuromyelitis Optica Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Drugs for Neuromyelitis Optica Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Drugs for Neuromyelitis Optica Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Drugs for Neuromyelitis Optica Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Drugs for Neuromyelitis Optica by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Drugs for Neuromyelitis Optica by Type (2020-2031)
 Figure 55. Global Drugs for Neuromyelitis Optica Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Drugs for Neuromyelitis Optica by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Drugs for Neuromyelitis Optica by Application (2020-2031)
 Figure 58. Global Drugs for Neuromyelitis Optica Price (US$/Unit) by Application (2020-2031)
 Figure 59. Drugs for Neuromyelitis Optica Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Neuromyelitis Optica Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neuromyelitis Optica Drug Market Research Report 2025
Neuromyelitis Optic Spectrum Disorder Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neuromyelitis Optica Spectrum Disorders NMOSD Market Research Report 2024
Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Research Report 2024
Global Devic s Syndrome Neuromyelitis Optica Treatment Market Insights Forecast to 2030
Multiple Sclerosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Optic Neuritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Optic Neuritis Drug Market Research Report 2025
Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Transverse Myelitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Transverse Myelitis Diagonosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Demyelinating Diseases Therapeutics Market Research Report 2024
Ischemic Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs for Central Nervous System Diseases Market Insights Forecast to 2030
Global Meningitis Medication Market Research Report 2024
Global Nervous System Chemicals Market Research Report 2024
Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030
Encephalomyelitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Research Report 2025

RELATED REPORTS

Global Autism Drug Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9T16706
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global ADHD Planner App Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34C16185
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Autism Digital Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2E16662
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-25A16539
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions